Document is current
Any future updates will be listed below
-
Authors
Ashford, Anne L. https://orcid.org/0009-0008-5465-5455
Nachmanson, Daniela https://orcid.org/0000-0001-9792-379X
Wills, John W. https://orcid.org/0000-0002-4347-5394
Higgins, Jacob E. https://orcid.org/0000-0002-4984-5456
Smith, Thomas H. https://orcid.org/0000-0002-8798-7228
Vavra, Kevin C. https://orcid.org/0000-0002-8723-0401
Dahalan, Farah A. https://orcid.org/0000-0002-4215-0715
Howe, Jonathan https://orcid.org/0009-0004-5204-3544
Elloway, Joanne M. https://orcid.org/0000-0002-1857-5887
Salk, Jesse J. https://orcid.org/0000-0002-7804-0550
Doherty, Ann https://orcid.org/0009-0001-8156-6422
Lynch, Anthony M. https://orcid.org/0000-0002-1533-7664
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 25 June 2025
First Online: 17 July 2025
Declarations
:
: AA, AD, FD and JE are employees of AstraZeneca and have shares in AstraZeneca. DN, JEH, JS, KV and TS were employed at TwinStrand Biosciences at the time the work was conducted and JEH, KV and TS have shares in TwinStrand Biosciences. JS is the founder, and has shares in, TwinStrand Biosciences and receives Duplex Sequencing Patent Royalties from the University of Washington. AL, JH and JW are employees of GSK and have shares in GSK.
: All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.
